Spanish Español English English

Leader in biosolutions for pharmaceutical
and agro-food industry

News

    • 26 AUG 15
    Neuron Bio patents its neuroprotective compound in Japan

    Neuron Bio patents its neuroprotective compound in Japan

    Last year the company was granted with the European patent to protect its compound NST0037. The Japanese Patent Office (JPO) granted to Neuron Bio the patent “”Neuroprotective, hypocholesterolemic and antiepileptic compound”, which protects the molecule NST0037 as product and as use for the prevention and treatment of various pathologies of the Central Nervous System among

    • 15 JUL 15
    The incorporation of Neol Bio to the MAB stock market enhances the biotech sector

    The incorporation of Neol Bio to the MAB stock market enhances the biotech sector

    Neol Bio, subsidiary of Neuron Bio (NEU.MAB), has received requests of qualified investors for the subscription of 100% for the capital increase that arises up to €1.55 million and was approved on 26 June by its Board of Directors, thus it will be totally subscribed within the timeframe set out. The subscription conditions suppose a

    • 06 JUL 15
    Neuron Bio discovers a potential use for its molecule NST0076 for the treatment of Fragile X Syndrome

    Neuron Bio discovers a potential use for its molecule NST0076 for the treatment of Fragile X Syndrome

    Experiments carried out by Neuron Bio in collaboration with Dr. Patricia Cogram of the University of Chile and financed by FRAXA Research Foundation, have shown promising results of the compound NST0076 to treat fragile X syndrome (FXS). The fragile X syndrome is the most frequent genetic syndrome that causes hereditary intellectual disability and one of

    • 22 JUN 15
    Scientific milestones of Neuron Bio consolidate its strength in its 10th anniversary

    Scientific milestones of Neuron Bio consolidate its strength in its 10th anniversary

    Fernando Valdivieso, the president of Neuron Bio stated at the Shareholders’ Ordinary General Meeting during the previous press conference “scientific milestones achieved by Neuron Bio and its subsidiary Neol Bio have consolidated the Andalusia company as a reference in the biotech sector in Europe and we start to pave the way for USA”. The repurchase

MAB

  • Neuron Bio is listed on the Alternative Investment Market (MAB) in Spain

    Mercado alternativo bursatil
  • Uso de cookies

    Utilizamos cookies propias y de terceros para realizar análisis de uso y de medición de nuestra web para mejorar nuestros servicios. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.